Advances and Challenges in Gynecologic Cancer Treatment
October 8th 2024
A clinical trial is evaluating CBX-12 as a potential treatment for ovarian cancer, with plans to extend studies to other solid tumor types.
September 14th 2024
Research presented mixed results on the effectiveness of combining Keytruda with chemotherapy, with or without radiation, for high-risk endometrial cancer patients post-surgery.
September 11th 2024
Patients with gynecologic cancers are reminded of the benefits of participating in clinical trials and the importance of advocating for their consideration in such studies.
September 10th 2024
Surgery remains a common treatment for gynecologic cancers, with each surgical method offering its own set of advantages and disadvantages.
September 9th 2024
Understanding the molecular characteristics of gynecologic cancer is crucial for patients following diagnosis, aiding in personalized treatment approaches.
August 1st 2024
The FDA approved Jemperli in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent endometrial cancer.
July 30th 2024
Patients with advanced gynecologic cancer who received IMNN-001 alongside presurgical chemotherapy experienced a survival benefit of nearly a year longer.
July 29th 2024
An investigational new drug application was submitted for a novel antibody-drug conjugate targeting gynecologic and lung cancers.
July 2nd 2024
New drug approvals have expanded treatment options for endometrial cancer patients, including those with dMMR and pMMR disease types.
July 1st 2024
The FDA issued six approvals in June for treatments targeting various solid tumors, including thyroid, endometrial, colorectal, breast, and ovarian cancers.